# Delix Therapeutics

> Clinical-stage neuroscience biotech developing non-hallucinogenic neuroplastogen medicines.

## Why it is interesting

Its $100M November 2026 Series C led by strategic and specialist investors funds planned Phase IIb work; clinical proof of concept is the main value milestone.

## Profile

- **Latest funding:** Series C — $100M (November 9, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $100M
- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-11-13
- **Latest funding investors:** Johnson & Johnson Innovation – JJDC, SV Health Investors' Dementia Discovery Fund, RA Capital Management, UC Investments

## Funding history

- Series C · $100M · November 9, 2026
  Source: https://delixtherapeutics.com/news/delix-closes-100-million-series-c-financing/

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 13, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/delix-therapeutics